Navigation Links
Bavarian Nordic A/S - Half Year Interim Report 2009
Date:8/28/2009

KVISTGAARD, Denmark, August 28 /PRNewswire-FirstCall/ -- Today Bavarian Nordic published the company's half-year interim report 2009. The full financial statements are available on the company's website: http://www.bavarian-nordic.com. Below is an extract of the most significant matters in the report as well as events after the balance sheet date.

In the first half of 2009 Bavarian Nordic generated revenue of DKK 33 million and recorded a loss before tax of DKK 188 million. As of 30 June 2009 the Group's net free liquidity was DKK 489 million.

Bavarian Nordic's new prostate cancer vaccine - PROSTVAC(TM) has been further validated and shows blockbuster potential. Bavarian Nordic is progressing the development and Phase III preparations of PROSTVAC(TM):

    - End of phase II meeting with the FDA in Q4, 2009 and expected
      initiation of Phase III in 2010
    - Five ongoing clinical Phase I and II studies in different patient
      populations
    - Preparing the production for Phase III studies
    - Scientific publication of data
    - Ongoing discussions with prospective licensing partners

The U.S. Food and Drug Administration (FDA) has performed a GMP inspection of the IMVAMUNE(R) manufacturing facilities. These GMP inspections occurred at both Bavarian Nordic's Kvistgaard facility and at IDT in May 2009. The management of Bavarian Nordic consider these inspections to be successfully completed, and the corrective actions triggered by the inspections will be implemented within short time, causing no further investments. Bavarian Nordic has an ongoing and positive dialogue with FDA which confirms the expectations to start deliveries of IMVAMUNE(R) under the RFP-3 contract following the satisfactory implementation of the corrective actions. On this background the company expects delive
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordic Publishes its Annual Results 2008
8. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
9. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
10. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
11. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced ... - Global Strategic Business Report" report to their offering. ... Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The report ... , Europe , Asia-Pacific ... are provided for the period 2012 through 2020. Market data ...
(Date:8/19/2014)... 2014 XenoTech announces an exclusive ... metabolite production from bioactive small molecules. Based ... technology enables convenient and timely assessment of critical ... Vice President of Commercial Operations, Christian Darabant, “the ... risk can be measured directly by comparison with ...
(Date:8/19/2014)... 2014 CSSi, the leader in patient recruitment ... formation of the company,s Medical and Clinical Advisory Board ... Dr. William E. Gannon, Jr. to the ... The MCAB, with Dr. Gannon,s leadership, will ... and set strategic goals for the advancement and development ...
(Date:8/19/2014)... Aug. 19, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... today that its novel C. difficile ... th Interscience Conference on Antimicrobial Agents and ... D.C. Synthetic Biologics, Senior ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... Workforce Alliance, the,non- profit organization that manages job ... grant program that enabled over ninety professionals,to upgrade ... life sciences and,biotechnology-related industries over the past three ... Grant was,funded by the U.S. Department of Labor,s ...
... International,Corporation (Nasdaq: PRXL ), a leading global ... M.D., formerly Head,of Global Pharmaceutical Development at F. ... of Directors., Dr. Holdener was recently appointed ... biotechnology Company develops new therapeutic,agents in the field ...
... FRANCISCO, Jan. 9 Burrill Merchant Banking acted ... partnering of Gattex(TM) (teduglutide) with Nycomed.,Under the terms ... Gattex outside,North America to Nycomed for the treatment ... analog in development for the treatment of,short-bowel syndrome ...
Cached Biology Technology:Workforce Alliance Concludes Three-Year Biotech Training Program 2PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors 2PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors 3PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors 4Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement 2
(Date:8/20/2014)... a chili pepper causes a burning spiciness that is ... the chili pepper,s effect are using their findings to ... pain, which can be caused by inflammation or other ... is being tested in clinical trials, in ACS, ... colleagues explain that decades ago, scientists had pegged a ...
(Date:8/20/2014)... about 4,000 members, it triggers an important first stage ... type of comb used for rearing male reproductive, called ... Neurobiology and Behaviour at Cornell University, led by Michael ... colonies. The results are published in Springer,s journal ... Reproduction isn,t always a honeybee colony,s top priority. ...
(Date:8/19/2014)... increasing caesarean section rate, suggests a new commentary published ... of Obstetrics and Gynaecology (BJOG) . , China has ... world. Of 16 million babies born in 2010, approximately ... not known, the current Chinese language literature on caesarean ... 36% to 58%. However, before the 1980s, the caesarean ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
... Global Rainmakers, Inc., an intellectual property holding company ... has exited its "stealth" mode and is prepared to ... cutting-edge biometric security offerings. , During the past four ... dollars to develop and deploy a series of core--but ...
... Oct. 27, 2009 UT Southwestern Medical Center patient ... receive the newest generation of a mechanical device designed to ... awaits a heart transplant. Called a left-ventricular assist device ... pump blood throughout the body. For Mr. LeBlanc, it will ...
... discovered the pivotal role that volcanoes played in a ... ironically, these volcanoes first caused global warming -- by ... When they stopped erupting, Earth,s climate was thrown ... discovery underscores the importance of carbon in Earth,s climate ...
Cached Biology News:Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3UT Southwestern patient first in North Texas to receive newest-generation heart failure device 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 3Volcanoes played pivotal role in ancient ice age, mass extinction 2Volcanoes played pivotal role in ancient ice age, mass extinction 3
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Viruses microRNA Microarray contains all known ...
... At the forefront of Agilent analytical solutions ... local area networking (LAN) allows you to ... fast and informed decision making. Just as ... all the flexibility and performance needed for ...
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
Biology Products: